Suspension of sales of Sibutramine

The Vigilance Branch of HSA would like to update healthcare professionals on its regulatory decision to suspend the sales of sibutramine products with effect from 11 October 2010 following a benefit-risk assessment, which took into consideration the findings from the Sibutramine Cardiovascular Outcomes (SCOUT) study, the use of the product in the local context and developments in other international jurisdictions. The Vigilance Branch had consulted with its Pharmacovigilance Advisory Committee and a panel of external experts before arriving at this regulatory decision.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.